You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameButorphanol
Accession NumberDB00611  (APRD00835)
TypeSmall Molecule
GroupsApproved, Illicit, Vet Approved
DescriptionA synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain. [PubChem]
Structure
Thumb
Synonyms
(-)-17-(Cyclobutylmethyl)morphinan-3,14-diol
(-)-Butorphanol
(-)-N-Cyclobutylmethyl-3,14-dihydroxymorphinan
Butorfanol
Butorphanol
Butorphanolum
External Identifiers
  • BC-2627
  • levo-BC 2627
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Butorphanol Nasal Spraysolution10 mgnasalAa Pharma Inc2000-08-01Not applicableCanada
PMS-butorphanolspray10 mgnasalPharmascience Inc2002-06-07Not applicableCanada
Stadol NS - 10mg/ml Aem-liqmetered-dose aerosol; liquid10 mgnasalBristol Myers Squibb Canada1994-12-312004-08-04Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Butorphanol Tartratespray, metered10 mg/mLnasalA S Medication Solutions Llc2002-03-12Not applicableUs
Butorphanol Tartratespray, metered10 mg/mLnasalRoxane Laboratories, Inc2002-03-12Not applicableUs
Butorphanol Tartrateinjection, solution1 mg/mLintramuscular; intravenousHospira, Inc.1997-01-23Not applicableUs
Butorphanol Tartrateinjection2 mg/mLintramuscular; intravenousCardinal Health1998-10-15Not applicableUs
Butorphanol Tartrateinjection, solution1 mg/mLintramuscular; intravenousWest ward Pharmaceutical Corp2009-05-01Not applicableUs
Butorphanol Tartrateinjection, solution2 mg/mLintramuscular; intravenousHospira, Inc.1997-01-23Not applicableUs
Butorphanol Tartrateinjection1 mg/mLintramuscular; intravenousCardinal Health1998-10-15Not applicableUs
Butorphanol Tartrateinjection, solution2 mg/mLintramuscular; intravenousWest ward Pharmaceutical Corp2009-05-01Not applicableUs
Butorphanol Tartrateinjection, solution2 mg/mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc2013-08-14Not applicableUs
Butorphanol Tartratesolution10 mg/mLnasalApotex Corp.2002-12-04Not applicableUs
Butorphanol Tartratespray10 mg/mLnasalMylan Pharmaceuticals Inc.2011-01-21Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ButaroLotus Pharmaceuticals
ButrumAristo
StadolBristol-Myers Squibb
Stadol NSCephalon
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Butorphanol Tartrate
58786-99-5
Thumb
  • InChI Key: GMTYREVWZXJPLF-AFHUBHILSA-N
  • Monoisotopic Mass: 477.236267101
  • Average Mass: 477.5473
DBSALT000276
Categories
UNIIQV897JC36D
CAS number42408-82-2
WeightAverage: 327.4605
Monoisotopic: 327.219829177
Chemical FormulaC21H29NO2
InChI KeyInChIKey=IFKLAQQSCNILHL-QHAWAJNXSA-N
InChI
InChI=1S/C21H29NO2/c23-17-7-6-16-12-19-21(24)9-2-1-8-20(21,18(16)13-17)10-11-22(19)14-15-4-3-5-15/h6-7,13,15,19,23-24H,1-5,8-12,14H2/t19-,20+,21-/m1/s1
IUPAC Name
(1S,9R,10S)-17-(cyclobutylmethyl)-17-azatetracyclo[7.5.3.0¹,¹⁰.0²,⁷]heptadeca-2(7),3,5-triene-4,10-diol
SMILES
[H][C@@]12CC3=C(C=C(O)C=C3)[C@]3(CCCC[C@@]13O)CCN2CC1CCC1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassMorphinans
Sub ClassNot Available
Direct ParentMorphinans
Alternative Parents
Substituents
  • Morphinan
  • Benzylisoquinoline
  • Phenanthrene
  • Benzazocine
  • Tetralin
  • Aralkylamine
  • Benzenoid
  • Piperidine
  • Tertiary alcohol
  • Cyclic alcohol
  • Tertiary aliphatic amine
  • Tertiary amine
  • 1,2-aminoalcohol
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the relief of moderate to severe pain.
PharmacodynamicsButorphanol is a synthetic opioid agonist-antagonist analgesic with a pharmacological and therapeutic profile that has been well established since its launch as a parenteral formulation in 1978. The introduction of a transnasal formulation of butorphanol represents a new and noninvasive presentation of an analgesic for moderate to severe pain. This route of administration bypasses the gastrointestinal tract, and this is an advantage for a drug such as butorphanol that undergoes significant first-pass metabolism after oral administration. The onset of action and systemic bioavailability of butorphanol following transnasal delivery are similar to those after parenteral administration. Butorphanol blocks pain impulses at specific sites in the brain and spinal cord.
Mechanism of actionThe exact mechanism of action is unknown, but is believed to interact with an opiate receptor site in the CNS (probably in or associated with the limbic system). The opiate antagonistic effect may result from competitive inhibition at the opiate receptor, but may also be a result of other mechanisms. Butorphanol is a mixed agonist-antagonist that exerts antagonistic or partially antagonistic effects at mu opiate receptor sites, but is thought to exert its agonistic effects principally at the kappa and sigma opiate receptors.
Related Articles
AbsorptionRapidly absorbed after intramuscular injection and peak plasma levels are reached in 20-40 minutes. The absolute bioavailability is 60-70% and is unchanged in patients with allergic rhinitis. In patients using a nasal vasoconstrictor (oxymetazoline) the fraction of the dose absorbed was unchanged, but the rate of absorption was slowed. Oral bioavailability is only 5-17% because of extensive first-pass metabolism.
Volume of distribution
  • 305 to 901 L
Protein bindingSerum protein binding is approximately 80%.
Metabolism

Extensively metabolized in the liver. The pharmacological activity of butorphanol metabolites has not been studied in humans; in animal studies, butorphanol metabolites have demonstrated some analgesic activity.

Route of eliminationButorphanol is extensively metabolized in the liver. Elimination occurs by urine and fecal excretion.
Half lifeThe elimination half-life of butorphanol is about 18 hours. In renally impaired patients with creatinine clearances <30 mL/min the elimination half-life is approximately doubled. After intravenous administration to patients with hepatic impairment, the elimination half-life of butorphanol was approximately tripled.
Clearance
  • 99 +/- 23 L/h [Young with IV 2 mg]
  • 82 +/- 21 [Eldery with IV 2 mg]
ToxicityThe clinical manifestations of butorphanol overdose are those of opioid drugs in general. The most serious symptoms are hypoventilation, cardiovascular insufficiency, coma, and death.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9798
Blood Brain Barrier+0.9463
Caco-2 permeable+0.6844
P-glycoprotein substrateSubstrate0.8494
P-glycoprotein inhibitor IInhibitor0.5
P-glycoprotein inhibitor IIInhibitor0.5667
Renal organic cation transporterInhibitor0.6508
CYP450 2C9 substrateNon-substrate0.8248
CYP450 2D6 substrateSubstrate0.509
CYP450 3A4 substrateSubstrate0.5842
CYP450 1A2 substrateNon-inhibitor0.6532
CYP450 2C9 inhibitorNon-inhibitor0.9094
CYP450 2D6 inhibitorInhibitor0.6572
CYP450 2C19 inhibitorNon-inhibitor0.8456
CYP450 3A4 inhibitorNon-inhibitor0.8744
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9017
Ames testNon AMES toxic0.7587
CarcinogenicityNon-carcinogens0.9573
BiodegradationNot ready biodegradable0.9368
Rat acute toxicity2.6466 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5378
hERG inhibition (predictor II)Inhibitor0.5983
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Bedford laboratories div ben venue laboratories inc
  • Claris lifesciences ltd
  • Hikma farmaceutica (portugal) sa
  • Hikma farmaceutica sa
  • Hospira inc
  • Apothecon inc div bristol myers squibb
  • Mylan pharmaceuticals inc
  • Novex pharma
  • Roxane laboratories inc
  • Bristol myers squibb co pharmaceutical research institute
Packagers
Dosage forms
FormRouteStrength
Solutionnasal10 mg
Injectionintramuscular; intravenous1 mg/mL
Injectionintramuscular; intravenous2 mg/mL
Injection, solutionintramuscular; intravenous1 mg/mL
Injection, solutionintramuscular; intravenous2 mg/mL
Solutionnasal10 mg/mL
Spraynasal10 mg/mL
Spray, meterednasal10 mg/mL
Spraynasal10 mg
Metered-dose aerosol; liquidnasal10 mg
Prices
Unit descriptionCostUnit
Butorphanol Tartrate 10 mg/ml Solution 2.5ml Bottle56.99USD bottle
Butorphanol 10 mg/ml spray39.63USD ml
Stadol 2 mg/ml vial10.11USD ml
Butorphanol 2 mg/ml vial7.2USD ml
Butorphanol 1 mg/ml vial3.6USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point272-274Monkovic, I. and Conway, T.T.; U.S. Patent 3,775,414; November 27,1973; Monkovic, I.,Wong, H. and Lim, G.; U.S. Patent 3,980,641; September 14, 1976; Pachter, IJ., Belleau, B.R. and Monkovic, I.; U.S. Patent 3,819,635; June 25,1974; and Lim, G. and Hooper, J.W.; U.S. Patent 4,017,497; April 12,1977; all assigned to Bristol-Myers Company.
water solubilityModerateNot Available
logP3.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.16 mg/mLALOGPS
logP3.65ALOGPS
logP2.89ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)9.86ChemAxon
pKa (Strongest Basic)10.7ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area43.7 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity95.92 m3·mol-1ChemAxon
Polarizability37.94 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Monkovic, I. and Conway, T.T.; U.S. Patent 3,775,414; November 27,1973; Monkovic, I.,Wong, H. and Lim, G.; U.S. Patent 3,980,641; September 14, 1976; Pachter, IJ., Belleau, B.R. and Monkovic, I.; U.S. Patent 3,819,635; June 25,1974; and Lim, G. and Hooper, J.W.; U.S. Patent 4,017,497; April 12,1977; all assigned to Bristol-Myers Company.

General References
  1. Gear RW, Miaskowski C, Gordon NC, Paul SM, Heller PH, Levine JD: The kappa opioid nalbuphine produces gender- and dose-dependent analgesia and antianalgesia in patients with postoperative pain. Pain. 1999 Nov;83(2):339-45. [PubMed:10534607 ]
  2. Fan LW, Tanaka S, Tien LT, Ma T, Rockhold RW, Ho IK: Withdrawal from dependence upon butorphanol uniquely increases kappa(1)-opioid receptor binding in the rat brain. Brain Res Bull. 2002 Jun;58(2):149-60. [PubMed:12127012 ]
External Links
ATC CodesN02AF01
AHFS Codes
  • 28:08.12
PDB EntriesNot Available
FDA labelDownload (320 KB)
MSDSDownload (60.6 KB)
Interactions
Drug Interactions
Drug
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Butorphanol.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Butorphanol.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Butorphanol is combined with 7-Nitroindazole.
AcepromazineAcepromazine may increase the hypotensive activities of Butorphanol.
AcepromazineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Aceprometazine.
AcetazolamideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Acetazolamide.
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Butorphanol.
adipiplonThe risk or severity of adverse effects can be increased when Butorphanol is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Alfaxalone.
AlfentanilButorphanol may decrease the analgesic activities of Alfentanil.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Butorphanol.
AlimemazineAlimemazine may increase the hypotensive activities of Butorphanol.
AlphacetylmethadolButorphanol may decrease the analgesic activities of Alphacetylmethadol.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Butorphanol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Butorphanol.
AlvimopanThe risk or severity of adverse effects can be increased when Butorphanol is combined with Alvimopan.
AmilorideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Amiloride.
AmisulprideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Amitriptyline.
Ammonium chlorideAmmonium chloride may increase the excretion rate of Butorphanol which could result in a higher serum level.
AmobarbitalThe risk or severity of adverse effects can be increased when Butorphanol is combined with Amobarbital.
AmoxapineButorphanol may increase the serotonergic activities of Amoxapine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Butorphanol.
AmperozideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Amperozide.
AmphetamineAmphetamine may increase the analgesic activities of Butorphanol.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Butorphanol.
AripiprazoleThe risk or severity of adverse effects can be increased when Butorphanol is combined with Aripiprazole.
ArticaineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Asenapine.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Butorphanol.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Butorphanol.
AzaperoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Azaperone.
AzelastineButorphanol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Butorphanol.
AzosemideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Azosemide.
BaclofenThe risk or severity of adverse effects can be increased when Butorphanol is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Butorphanol is combined with Barbital.
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Butorphanol.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Bendroflumethiazide.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Butorphanol.
BenzocaineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Benzocaine.
BenzphetamineBenzphetamine may increase the analgesic activities of Butorphanol.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Butorphanol is combined with Benzyl alcohol.
BezitramideButorphanol may decrease the analgesic activities of Bezitramide.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Butorphanol.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Butorphanol is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.
BrimonidineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Brotizolam.
BumetanideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Butorphanol.
BuprenorphineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Butorphanol.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Butorphanol.
ButacaineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Butorphanol is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Butorphanol is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Butorphanol is combined with Butethal.
Canrenoic acidThe risk or severity of adverse effects can be increased when Butorphanol is combined with Canrenoic acid.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Butorphanol.
CarbinoxamineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Carbinoxamine.
CarfentanilButorphanol may decrease the analgesic activities of Carfentanil.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Butorphanol.
CarisoprodolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Carisoprodol.
CetirizineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Butorphanol is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Butorphanol.
ChlormezanoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Chloroprocaine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Chlorphenamine.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Butorphanol.
ChlorphentermineChlorphentermine may increase the analgesic activities of Butorphanol.
ChlorpromazineChlorpromazine may increase the hypotensive activities of Butorphanol.
ChlorpromazineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Chlorprothixene.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Butorphanol.
CitalopramButorphanol may increase the serotonergic activities of Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Butorphanol is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Butorphanol is combined with clomethiazole.
ClomipramineButorphanol may increase the serotonergic activities of Clomipramine.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Butorphanol.
ClonazepamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Butorphanol is combined with Clorazepate.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Butorphanol.
CocaineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Cocaine.
CodeineButorphanol may decrease the analgesic activities of Codeine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Butorphanol.
ConivaptanThe risk or severity of adverse effects can be increased when Butorphanol is combined with Conivaptan.
CyclizineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Cyclobenzaprine.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Butorphanol.
CyclothiazideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Cyclothiazide.
CyproheptadineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Butorphanol.
DapoxetineButorphanol may increase the serotonergic activities of Dapoxetine.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Butorphanol.
deramciclaneThe risk or severity of adverse effects can be increased when Butorphanol is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Butorphanol.
DesmopressinThe risk or severity of adverse effects can be increased when Butorphanol is combined with Desmopressin.
DetomidineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Dexbrompheniramine.
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Butorphanol.
DexmedetomidineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Dexmedetomidine.
DextroamphetamineDextroamphetamine may increase the analgesic activities of Butorphanol.
DextromoramideButorphanol may decrease the analgesic activities of Dextromoramide.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Butorphanol.
DextropropoxypheneButorphanol may decrease the analgesic activities of Dextropropoxyphene.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Butorphanol.
DezocineButorphanol may decrease the analgesic activities of Dezocine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Butorphanol.
DiazepamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Diazepam.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Butorphanol.
DifenoxinThe risk or severity of adverse effects can be increased when Butorphanol is combined with Difenoxin.
DihydrocodeineButorphanol may decrease the analgesic activities of Dihydrocodeine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Butorphanol.
DihydroetorphineButorphanol may decrease the analgesic activities of Dihydroetorphine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Butorphanol.
DihydromorphineButorphanol may decrease the analgesic activities of Dihydromorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Butorphanol.
DimenhydrinateThe risk or severity of adverse effects can be increased when Butorphanol is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Diphenhydramine.
DiphenoxylateButorphanol may decrease the analgesic activities of Diphenoxylate.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Butorphanol.
DoramectinThe risk or severity of adverse effects can be increased when Butorphanol is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Butorphanol is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.
DoxylamineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Doxylamine.
DPDPEButorphanol may decrease the analgesic activities of DPDPE.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Butorphanol.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Butorphanol.
DrospirenoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Drospirenone.
DrotebanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Dyclonine.
EcgonineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Butorphanol is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Butorphanol is combined with Efavirenz.
EfonidipineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Efonidipine.
EluxadolineButorphanol may increase the constipating activities of Eluxadoline.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Butorphanol.
EntacaponeThe risk or severity of adverse effects can be increased when Butorphanol is combined with Entacapone.
EplerenoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Eplerenone.
EscitalopramButorphanol may increase the serotonergic activities of Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Butorphanol.
Etacrynic acidThe risk or severity of adverse effects can be increased when Butorphanol is combined with Etacrynic acid.
EthanolButorphanol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Butorphanol.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Butorphanol.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Butorphanol.
EthosuximideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ethotoin.
EthoxzolamideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ethoxzolamide.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ethyl loflazepate.
EthylmorphineButorphanol may decrease the analgesic activities of Ethylmorphine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Butorphanol.
EtidocaineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Butorphanol.
EtoperidoneButorphanol may increase the serotonergic activities of Etoperidone.
EtorphineButorphanol may decrease the analgesic activities of Etorphine.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Butorphanol.
EzogabineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Butorphanol is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Fencamfamine.
FenfluramineButorphanol may increase the serotonergic activities of Fenfluramine.
FentanylButorphanol may decrease the analgesic activities of Fentanyl.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Butorphanol.
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Butorphanol.
FexofenadineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Butorphanol is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Flunitrazepam.
FluoxetineButorphanol may increase the serotonergic activities of Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Flupentixol.
FluphenazineFluphenazine may increase the hypotensive activities of Butorphanol.
FluphenazineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Butorphanol is combined with Fluticasone Propionate.
FluvoxamineButorphanol may increase the serotonergic activities of Fluvoxamine.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Butorphanol.
FosphenytoinThe risk or severity of adverse effects can be increased when Butorphanol is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Fospropofol.
FurosemideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Furosemide.
GabapentinThe risk or severity of adverse effects can be increased when Butorphanol is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Butorphanol is combined with gabapentin enacarbil.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Butorphanol.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Butorphanol is combined with Gamma Hydroxybutyric Acid.
GlutethimideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Glutethimide.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Butorphanol.
GuanfacineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Halazepam.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Butorphanol.
HalothaneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Halothane.
HeroinButorphanol may decrease the analgesic activities of Heroin.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Butorphanol.
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Butorphanol.
HexobarbitalThe risk or severity of adverse effects can be increased when Butorphanol is combined with Hexobarbital.
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Butorphanol.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Hydrochlorothiazide.
HydrocodoneButorphanol may decrease the analgesic activities of Hydrocodone.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Butorphanol.
HydroflumethiazideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Hydroflumethiazide.
HydromorphoneButorphanol may decrease the analgesic activities of Hydromorphone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Butorphanol.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Butorphanol.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.
HydroxyzineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Hydroxyzine.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Butorphanol.
IloperidoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Imipramine.
IndalpineButorphanol may increase the serotonergic activities of Indalpine.
IndapamideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Indapamide.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Butorphanol.
IsofluraneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Isoflurane.
IsosorbideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Isosorbide.
KetamineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ketazolam.
KetobemidoneButorphanol may decrease the analgesic activities of Ketobemidone.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Butorphanol.
KW-3902The risk or severity of adverse effects can be increased when Butorphanol is combined with KW-3902.
LamotrigineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Butorphanol is combined with Levodopa.
Levomethadyl AcetateButorphanol may decrease the analgesic activities of Levomethadyl Acetate.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Butorphanol.
LevomilnacipranButorphanol may increase the serotonergic activities of Levomilnacipran.
LevorphanolButorphanol may decrease the analgesic activities of Levorphanol.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Butorphanol.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Butorphanol.
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Butorphanol.
LithiumThe risk or severity of adverse effects can be increased when Butorphanol is combined with Lithium.
LofentanilButorphanol may decrease the analgesic activities of Lofentanil.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Butorphanol.
LoratadineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Butorphanol.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Butorphanol.
Lu AA21004Butorphanol may increase the serotonergic activities of Lu AA21004.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Butorphanol.
LurasidoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Butorphanol is combined with Magnesium Sulfate.
MannitolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Mannitol.
MaprotilineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Maprotiline.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Butorphanol.
MeclizineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Butorphanol is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Melperone.
MephentermineMephentermine may increase the analgesic activities of Butorphanol.
MepivacaineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Butorphanol.
MersalylThe risk or severity of adverse effects can be increased when Butorphanol is combined with Mersalyl.
MesoridazineMesoridazine may increase the hypotensive activities of Butorphanol.
MesoridazineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Metaxalone.
MethadoneButorphanol may decrease the analgesic activities of Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Butorphanol.
Methadyl AcetateButorphanol may decrease the analgesic activities of Methadyl Acetate.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Butorphanol.
MethamphetamineMethamphetamine may increase the analgesic activities of Butorphanol.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Butorphanol.
MethapyrileneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methaqualone.
MethazolamideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Butorphanol.
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Butorphanol.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methsuximide.
MethyclothiazideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methyclothiazide.
Methylene blueMethylene blue may increase the hypotensive activities of Butorphanol.
MethylnaltrexoneThe risk or severity of adverse effects can be increased when Methylnaltrexone is combined with Butorphanol.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methylphenobarbital.
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Butorphanol.
MetolazoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Metolazone.
MetyrosineButorphanol may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Midazolam.
MilnacipranButorphanol may increase the serotonergic activities of Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.
MirtazapineButorphanol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Butorphanol.
MolindoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Molindone.
MoricizineMoricizine may increase the hypotensive activities of Butorphanol.
MorphineButorphanol may decrease the analgesic activities of Morphine.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Butorphanol.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Butorphanol.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.
NabiloneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Nalbuphine.
NaloxegolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Naloxegol.
NaltrexoneThe therapeutic efficacy of Butorphanol can be decreased when used in combination with Naltrexone.
NitrazepamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Nitrous oxide.
NormethadoneButorphanol may decrease the analgesic activities of Normethadone.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Butorphanol.
NortriptylineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Nortriptyline.
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Butorphanol.
OlanzapineButorphanol may increase the serotonergic activities of Olanzapine.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Butorphanol.
OlopatadineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ondansetron.
OpiumButorphanol may decrease the analgesic activities of Opium.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Butorphanol.
OrphenadrineButorphanol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Butorphanol.
OsanetantThe risk or severity of adverse effects can be increased when Butorphanol is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Oxazepam.
OxprenololThe risk or severity of adverse effects can be increased when Butorphanol is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Oxybuprocaine.
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Butorphanol.
OxycodoneButorphanol may decrease the analgesic activities of Oxycodone.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Butorphanol.
OxymorphoneButorphanol may decrease the analgesic activities of Oxymorphone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Butorphanol.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Butorphanol.
PaliperidoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Paliperidone.
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Butorphanol.
ParaldehydeButorphanol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Butorphanol.
ParoxetineButorphanol may increase the serotonergic activities of Paroxetine.
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Butorphanol.
PentazocineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Butorphanol.
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Butorphanol.
PerampanelThe risk or severity of adverse effects can be increased when Butorphanol is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Butorphanol is combined with Perospirone.
PerphenazinePerphenazine may increase the hypotensive activities of Butorphanol.
PerphenazineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Perphenazine.
PethidineButorphanol may decrease the analgesic activities of Pethidine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Butorphanol.
PhenobarbitalThe risk or severity of adverse effects can be increased when Butorphanol is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Phenoxyethanol.
PhenterminePhentermine may increase the analgesic activities of Butorphanol.
PhenytoinThe risk or severity of adverse effects can be increased when Butorphanol is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Pipamperone.
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Butorphanol.
PipotiazineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Pipotiazine.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Butorphanol.
PiretanideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Piretanide.
PizotifenThe risk or severity of adverse effects can be increased when Butorphanol is combined with Pizotifen.
PolythiazideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Pomalidomide.
PotassiumThe risk or severity of adverse effects can be increased when Butorphanol is combined with Potassium.
Potassium CitrateThe risk or severity of adverse effects can be increased when Butorphanol is combined with Potassium Citrate.
PramipexoleButorphanol may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Butorphanol.
PrilocaineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Prilocaine.
PrimidoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Procaine.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Butorphanol.
ProchlorperazineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Prochlorperazine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Butorphanol.
PromazinePromazine may increase the hypotensive activities of Butorphanol.
PromazineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Promazine.
PromethazinePromethazine may increase the hypotensive activities of Butorphanol.
PromethazineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Promethazine.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Butorphanol.
ProparacaineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Proparacaine.
PropofolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Butorphanol is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Quetiapine.
QuinethazoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Quinethazone.
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Butorphanol.
RamelteonThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ramelteon.
RamosetronButorphanol may increase the constipating activities of Ramosetron.
RemifentanilButorphanol may decrease the analgesic activities of Remifentanil.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Butorphanol.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Butorphanol.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Butorphanol.
RisperidoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Risperidone.
RomifidineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Romifidine.
RopiniroleButorphanol may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Butorphanol.
RotigotineButorphanol may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Butorphanol.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Butorphanol is combined with S-Ethylisothiourea.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Butorphanol.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Butorphanol.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Butorphanol.
SertindoleThe risk or severity of adverse effects can be increased when Butorphanol is combined with Sertindole.
SertralineButorphanol may increase the serotonergic activities of Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Sevoflurane.
Sodium oxybateThe risk or severity of adverse effects can be increased when Butorphanol is combined with Sodium oxybate.
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Butorphanol.
SpironolactoneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Spironolactone.
StiripentolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Stiripentol.
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Butorphanol.
SufentanilButorphanol may decrease the analgesic activities of Sufentanil.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Butorphanol.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Butorphanol.
SuvorexantThe risk or severity of adverse effects can be increased when Butorphanol is combined with Suvorexant.
TapentadolButorphanol may decrease the analgesic activities of Tapentadol.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Butorphanol.
TasimelteonThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tasimelteon.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Butorphanol.
TetrabenazineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tetrodotoxin.
ThalidomideButorphanol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Butorphanol.
TheobromineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Theobromine.
ThiamylalThe risk or severity of adverse effects can be increased when Butorphanol is combined with Thiamylal.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Butorphanol.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Butorphanol.
ThioridazineThioridazine may increase the hypotensive activities of Butorphanol.
ThioridazineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tiagabine.
TicrynafenThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ticrynafen.
TiletamineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tiletamine.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Butorphanol.
TizanidineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tolcapone.
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Butorphanol.
TolvaptanThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Butorphanol is combined with Topiramate.
TorasemideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Torasemide.
TramadolButorphanol may decrease the analgesic activities of Tramadol.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Butorphanol.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Tranylcypromine.
TrazodoneButorphanol may increase the serotonergic activities of Trazodone.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Butorphanol.
TriamtereneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Triamterene.
TriazolamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Triazolam.
TrichlormethiazideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Trichlormethiazide.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Butorphanol.
TrifluoperazineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Trifluoperazine.
TriflupromazineTriflupromazine may increase the hypotensive activities of Butorphanol.
TriflupromazineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Triflupromazine.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Butorphanol.
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Butorphanol.
TrimipramineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Triprolidine.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Butorphanol.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Butorphanol.
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Butorphanol.
UlaritideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ularitide.
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Butorphanol.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Butorphanol.
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Butorphanol.
VigabatrinThe risk or severity of adverse effects can be increased when Butorphanol is combined with Vigabatrin.
VilazodoneButorphanol may increase the serotonergic activities of Vilazodone.
VortioxetineButorphanol may increase the serotonergic activities of Vortioxetine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Butorphanol.
XylazineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Butorphanol is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ziconotide.
ZimelidineButorphanol may increase the serotonergic activities of Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Butorphanol.
ZolazepamThe risk or severity of adverse effects can be increased when Butorphanol is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Butorphanol.
ZonisamideThe risk or severity of adverse effects can be increased when Butorphanol is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Butorphanol is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Butorphanol is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Zuclopenthixol.
Food Interactions
  • Avoid alcohol.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Vivian JA, DeYoung MB, Sumpter TL, Traynor JR, Lewis JW, Woods JH: kappa-Opioid receptor effects of butorphanol in rhesus monkeys. J Pharmacol Exp Ther. 1999 Jul;290(1):259-65. [PubMed:10381785 ]
  2. Park Y, Jang CG, Ho IK, Ko KH: kappa-opioid agonist stimulated regional distribution of [(35)S]GTPgammas binding in butorphanol continuously infused rat. Brain Res Bull. 2000 May 1;52(1):17-20. [PubMed:10779697 ]
  3. Fan LW, Tanaka S, Tien LT, Ma T, Rockhold RW, Ho IK: Withdrawal from dependence upon butorphanol uniquely increases kappa(1)-opioid receptor binding in the rat brain. Brain Res Bull. 2002 Jun;58(2):149-60. [PubMed:12127012 ]
  4. Fan LW, Tanaka S, Park Y, Sasaki K, Ma T, Tien LT, Rockhold RW, Ho IK: Butorphanol dependence and withdrawal decrease hippocampal kappa 2-opioid receptor binding. Brain Res. 2002 Dec 27;958(2):277-90. [PubMed:12470863 ]
  5. Commiskey S, Fan LW, Ho IK, Rockhold RW: Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. J Pharmacol Sci. 2005 Jun;98(2):109-16. Epub 2005 Jun 8. [PubMed:15942128 ]
  6. Picker MJ, Benyas S, Horwitz JA, Thompson K, Mathewson C, Smith MA: Discriminative stimulus effects of butorphanol: influence of training dose on the substitution patterns produced by Mu, Kappa and Delta opioid agonists. J Pharmacol Exp Ther. 1996 Dec;279(3):1130-41. [PubMed:8968334 ]
  7. Wakabayashi H, Tokuyama S, Ho IK: Simultaneous measurement of biogenic amines and their metabolites in rat brain regions after acute administration of and abrupt withdrawal from butorphanol or morphine. Neurochem Res. 1995 Oct;20(10):1179-85. [PubMed:8746803 ]
  8. Narita M, Feng Y, Makimura M, Hoskins B, Ho IK: Repeated administration of opioids alters characteristics of membrane-bound phorbol ester binding in rat brain. Eur J Pharmacol. 1994 Dec 27;271(2-3):547-50. [PubMed:7705457 ]
  9. Ohta S, Niwa M, Nozaki M, Tsurumi K, Shimonaka H, Tanahashi T, Uematsu H, Yamamoto M, Fujimura H: [Kappa-type opioid receptor in human placental membrane]. Masui. 1989 Oct;38(10):1293-300. [PubMed:2555580 ]
  10. Walsh SL, Chausmer AE, Strain EC, Bigelow GE: Evaluation of the mu and kappa opioid actions of butorphanol in humans through differential naltrexone blockade. Psychopharmacology (Berl). 2008 Jan;196(1):143-55. Epub 2007 Oct 2. [PubMed:17909753 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Molecular Weight:
40368.235 Da
References
  1. Fan LW, Tanaka S, Tien LT, Ma T, Rockhold RW, Ho IK: Withdrawal from dependence upon butorphanol uniquely increases kappa(1)-opioid receptor binding in the rat brain. Brain Res Bull. 2002 Jun;58(2):149-60. [PubMed:12127012 ]
  2. Fan LW, Tanaka S, Park Y, Sasaki K, Ma T, Tien LT, Rockhold RW, Ho IK: Butorphanol dependence and withdrawal decrease hippocampal kappa 2-opioid receptor binding. Brain Res. 2002 Dec 27;958(2):277-90. [PubMed:12470863 ]
  3. Commiskey S, Fan LW, Ho IK, Rockhold RW: Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. J Pharmacol Sci. 2005 Jun;98(2):109-16. Epub 2005 Jun 8. [PubMed:15942128 ]
  4. Picker MJ, Benyas S, Horwitz JA, Thompson K, Mathewson C, Smith MA: Discriminative stimulus effects of butorphanol: influence of training dose on the substitution patterns produced by Mu, Kappa and Delta opioid agonists. J Pharmacol Exp Ther. 1996 Dec;279(3):1130-41. [PubMed:8968334 ]
  5. Wakabayashi H, Tokuyama S, Ho IK: Simultaneous measurement of biogenic amines and their metabolites in rat brain regions after acute administration of and abrupt withdrawal from butorphanol or morphine. Neurochem Res. 1995 Oct;20(10):1179-85. [PubMed:8746803 ]
  6. Narita M, Feng Y, Makimura M, Hoskins B, Ho IK: Repeated administration of opioids alters characteristics of membrane-bound phorbol ester binding in rat brain. Eur J Pharmacol. 1994 Dec 27;271(2-3):547-50. [PubMed:7705457 ]
  7. Walsh SL, Chausmer AE, Strain EC, Bigelow GE: Evaluation of the mu and kappa opioid actions of butorphanol in humans through differential naltrexone blockade. Psychopharmacology (Berl). 2008 Jan;196(1):143-55. Epub 2007 Oct 2. [PubMed:17909753 ]
  8. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
partial antagonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Vivian JA, DeYoung MB, Sumpter TL, Traynor JR, Lewis JW, Woods JH: kappa-Opioid receptor effects of butorphanol in rhesus monkeys. J Pharmacol Exp Ther. 1999 Jul;290(1):259-65. [PubMed:10381785 ]
  2. Fan LW, Tanaka S, Tien LT, Ma T, Rockhold RW, Ho IK: Withdrawal from dependence upon butorphanol uniquely increases kappa(1)-opioid receptor binding in the rat brain. Brain Res Bull. 2002 Jun;58(2):149-60. [PubMed:12127012 ]
  3. Fan LW, Tanaka S, Park Y, Sasaki K, Ma T, Tien LT, Rockhold RW, Ho IK: Butorphanol dependence and withdrawal decrease hippocampal kappa 2-opioid receptor binding. Brain Res. 2002 Dec 27;958(2):277-90. [PubMed:12470863 ]
  4. Commiskey S, Fan LW, Ho IK, Rockhold RW: Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. J Pharmacol Sci. 2005 Jun;98(2):109-16. Epub 2005 Jun 8. [PubMed:15942128 ]
  5. Picker MJ, Benyas S, Horwitz JA, Thompson K, Mathewson C, Smith MA: Discriminative stimulus effects of butorphanol: influence of training dose on the substitution patterns produced by Mu, Kappa and Delta opioid agonists. J Pharmacol Exp Ther. 1996 Dec;279(3):1130-41. [PubMed:8968334 ]
  6. Wakabayashi H, Tokuyama S, Ho IK: Simultaneous measurement of biogenic amines and their metabolites in rat brain regions after acute administration of and abrupt withdrawal from butorphanol or morphine. Neurochem Res. 1995 Oct;20(10):1179-85. [PubMed:8746803 ]
  7. Picker MJ: Discriminative stimulus effects of the mixed-opioid agonist/antagonist dezocine: cross-substitution by mu and delta opioid agonists. J Pharmacol Exp Ther. 1997 Dec;283(3):1009-17. [PubMed:9399970 ]
  8. Narita M, Feng Y, Makimura M, Hoskins B, Ho IK: Repeated administration of opioids alters characteristics of membrane-bound phorbol ester binding in rat brain. Eur J Pharmacol. 1994 Dec 27;271(2-3):547-50. [PubMed:7705457 ]
  9. Walsh SL, Chausmer AE, Strain EC, Bigelow GE: Evaluation of the mu and kappa opioid actions of butorphanol in humans through differential naltrexone blockade. Psychopharmacology (Berl). 2008 Jan;196(1):143-55. Epub 2007 Oct 2. [PubMed:17909753 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23